December 7, 2025 — Simcere Zaiming, an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd. (2096.HK), today announced that its Class 1 innovative biological drug, Enzeshu® (Suvemcitug for Injection), has been officially included in China’s National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug List. The inclusion will take effect on January 1, 2026. Enzeshu ’s inclusion in the National Medical Insurance Drug List within the same year of its market approval is expected to significantly alleviate patients’ financial burden and improve access to treatment.
Enzeshu® is China’s first vascular-targeted therapy approved for the treatment of the full population of patients with platinum-resistant recurrent ovarian cancer. It received marketing approval from the National Medical Products Administration (NMPA) of China on June 30, 2025. Ovarian cancer has the highest mortality rate among gynecological malignancies, and patients with platinum-resistant disease face a poor prognosis and limited treatment options. Prior to the approval of Enzeshu®, there was a significant unmet clinical need in this area.
Suvemcitug is a recombinant humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody. Its differentiated molecular epitope design enables precise blockade of the VEGF pathway. Preclinical studies have shown that Suvemcitug exhibits substantially greater potency in inhibiting VEGF binding to its receptors compared with similar anti-VEGF monoclonal antibodies, resulting in more pronounced anti-angiogenic and anti-tumor effects in preclinical models.
The pivotal Phase III SCORES study, led by Professor Wu Lingying of the Cancer Hospital of the Chinese Academy of Medical Sciences, demonstrated that Suvemcitug provided patients with platinum-resistant ovarian cancer with a significant improvement in progression-free survival (PFS), as well as a significant extension in overall survival (OS) and a reduction in the risk of death, while maintaining a favorable safety profile.
Based on these clinical data, the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Ovarian Cancer — Chinese Version, updated in November 2025, have listed Suvemcitug as a preferred regimen for the treatment of platinum-resistant recurrent ovarian cancer. In addition, Suvemcitug has been incorporated into several other Chinese clinical guidelines and expert consensus documents, including: the Chinese Guidelines for Clinical Practice in Gynecological Oncology (2025) as a Category I preferred recommendation; the Chinese Expert Consensus on the Diagnosis and Treatment of Platinum-Resistant Recurrent Ovarian Cancer (2025) with a Grade A strong recommendation; and the Chinese Society of Clinical Oncology (CSCO) Guidelines for Ovarian Cancer (2025) with a Level II recommendation.
Enzeshu® is manufactured at Simcere Zaiming’s antibody production facility located in the Nanjing Jiangbei New District. The company has established robust manufacturing capacity and a stable supply chain, enabling rapid nationwide availability through its commercial network covering more than 2,000 hospitals across China.
Another key product of Simcere Zaiming, Endostar® (Recombinant Human Endostatin Injection), has also been successfully transitioned to the conventional (non-negotiated) category of the National Medical Insurance Drug List. First included in the national insurance catalogue in 2017, Endostar® has become a cornerstone therapy for advanced non-small cell lung cancer in China. Its inclusion in the conventional category is expected to further enhance accessibility for a broader patient population.